Drug Profile
Rabies vaccine - Beijing Minhai Biotechnology
Alternative Names: Freeze dried rabies vaccine (MRC-5-cell) - Beijing Minhai Biotechnology; Freeze dried rabies vaccine - Beijing Minhai Biotechnology; HDCV rabies vaccine - Beijing Minhai Biotechnology; Human diploid cell rabies vaccine - Beijing Minhai Biotechnology; MRC-5 cell rabies vaccine - Beijing Minhai BiotechnologyLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Beijing Minhai Biotechnology
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rabies
Most Recent Events
- 20 Feb 2019 No development reported - Phase-III for Rabies (In adolescents, Prevention, In volunteers, In adults) in China (Parenteral)
- 15 Oct 2014 The Beijing Center for Disease Control and Prevention plans a phase III trial for Rabies (Prevention, In volunteers, In adolescents, In adults) in China (Parenteral) (NCT02288286)
- 15 Oct 2014 Beijing Center for Disease Control and Prevention in collaboration with Beijing Minhai Biotechnology plans a phase I trial for Rabies (Prevention, In adolescents, In adults, In volunteers) in China (Parenteral) (NCT02281396)